<DOC>
	<DOC>NCT03081494</DOC>
	<brief_summary>This is a phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer. The study will assess primarily the safety and tolerability and then the efficacy of PDR001 in combination with regorafenib. Particular attention will be paid to the level of activity of study drug combinations in CMS4 patients (retrospective analysis).</brief_summary>
	<brief_title>Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Key inclusion criteria: 1. Patients with metastatic colorectal adenocarcinoma. 2. Patients must provide a newly obtained or an archival tumor sample corresponding to CRC diagnosis (primary tumor) with sufficient tissue quality (qualified) for analysis 3. Patients must provide a newly obtained tumor tissue sample from a metastatic site 4. Patients with the presence of at least one lesion with measurable disease as per RECIST 5. Patients previously treated with two prior regimen as per standard of care and have experienced disease progression (including VEGF and EGFR targeted therapies (if KRAS wild). 6. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 01 Key exclusion criteria: 1. Patients with MSIH colorectal adenocarcinoma as defined per local assessment using standard of care testing 2. Patients with metastatic disease amenable to be resected with potentially curative surgery 3. Patients who have had chemotherapy, radiation, or biological cancer therapy within 14 days prior to the first dose of study treatment 4. Patients with a history of prior treatment with antiPD1, antiPDL1, antiPDL2, anti CTLA4 antibodies, other checkpoint inhibitors Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDR001</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>regorafenib</keyword>
	<keyword>CRC</keyword>
	<keyword>MMS</keyword>
	<keyword>CMS4</keyword>
	<keyword>ElevatION:CRC-102</keyword>
</DOC>